1/20 La Merie S.L. | Email [email protected]
| Internet www.lamerie.com
TOP 20 Biologics 2007 March 27, 2008 | Special Edition 1
TOP 20 Biologics 2007
• TOP 20 Blockbuster Drugs 2007
• TOP 13 Biologics Classes 2007
• Blockbuster Biologics 2007 by Class • Selected Other Recombinant Biologics
• Selected Other Non-Recombinant Biologics
Features:
March 27, 2008 Special Edition 1
March 27, 2008
Subscribe now!
2/20 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2007 March 27, 2008 | Special Edition 1
TOP 20 Biologics in 2007 ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication 2007 sales (vs 2006)
1 epoetin alfa; Epogen / ESPO / Procrit / Eprex
EPO-R Rhu protein Amgen & Kirin & Johnson & Johnson
Protein Renal and cancer anemia
US$ 5,764 mln (US$ 6,024)
2 etanercept; Enbrel / Embrel
TNF-alpha Rec fusion protein of Fc + sol TNF-R
Amgen & Wyeth & Takeda
Antibody Rheumatoid arthritis; psoriasis etc
US$ 5,453 mln (US$ 4,474)
3 rituximab; Rituxan / MabThera
CD20 Rec chimeric mab
Genentech/ Roche /Chugai Biogen IDEC, Zenyaku Kogyu
Antibody 1st line treat-ment of diffuse, large B-cell, CD20+ NHL plus chemotherapy
US$ 5,392 mln (US$ 3,912)
4 trastuzumab Herceptin
HER2 Rec huma-nized mab
Roche / Genentech
Antibody Metastatic breast cancer
US$ 4,743 mln (US$ 3,175)
5 infliximab Remicade;
TNF-alpha Rec chimeric mab
Centocor (J&J) & Schering-Plough & Tan-abe Seiyaku
Antibody Rheumatoid arthritis etc
US$ 4,465 mln (US$ 3,764)
6 bevacizumab Avastin
VEGF Rec humanized mab
Roche & Genentech
Antibody Metastatic colorectal cancer
US$ 4,014 mln (US$ 2,395)
7 darbepoetin Aranesp / NESP
EPO-R Rhu glycol-engineered protein
Amgen & Kirin Pharma
Protein Renal and cancer anemia
US$ 4,004 mln (US$ 4,121)
8 insulin analog glargine ; Lantus
Insulin receptor
Rhu insulin analog
Sanofi-Aventis Protein Diabetes mellitus
US$ 3,167 mln (US$ 2,188)
9 adalimumab; Humira
TNF-alpha Rec fully human mab
Abbott (& Eisai)
Antibody Rheumatoid arthritis, psoriasis etc
US$ 3,064 mln (US$ 2,044)
3/20 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2007 March 27, 2008 | Special Edition 1
TOP 20 Biologics in 2007 ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication 2007 sales (vs 2006)
10 Neulasta; peg-filgrastim
G-CSF-receptor
Pegylated rhu protein
Amgen Protein Neutropenia US$ 3,000 mln (US$ 2,710)
11 insulin analogs aspart / determir; Levemir; NovoLog (Mix)
Insulin receptor
Rhu insulin analogues
Novo Nordisk Protein Diabetes US$ 2,929 mln (US$ 1,908)
12 Human insulin; Actrapid / Novolin; Insulatard; Mixtard
Insulin receptor
Rhu proteins NovoNordisk Protein Diabetes US$ 2,629 mln (US$ 2,653)
13 epoetin beta; Neo-recormon / Epogin
EPO-R Rhu protein Roche & Chugai
Protein Renal and cancer anemia
US$ 2,047 mln (US$ 1,794)
14 interferon beta-1a Rebif
IFN-R Rhu protein Merck Serono Protein Multiple sclerosis US$ 1,875 mln (US$ 1,804)
15 inteferon beta-1a; Avonex
IFN-R Rhu protein Biogen Idec Protein Multiple sclerosis US$ 1,868 mln (US$ 1,707)
16 interferon beta-1b; Betaferon / Betaseron;
IFN-R Rhu protein Bayer Schering Pharma
Protein Multiple sclerosis US$ 1,603 mln (US$ 1,545)
4/20 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2007 March 27, 2008 | Special Edition 1
TOP 20 Biologics in 2007 ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication 2007 sales (vs 2006)
17 peginterfer-on alfa-2a; Pegasys
IFN-R Pegylated rec hu protein
Roche Protein Hepatitis B and C
US$ 1,600 mln (US$ 1,186)
18 Insulin analog lispro Humalog
Insulin receptor
Rhu insulin analog
Eli Lilly Protein Diabetes US$ 1,475 mln (US$ 1,300)
19 filgrastim Neupogen / GRAN
G-CSF-receptor
Rhu protein Amgen & Kirin Protein Neutropenia US$ 1,419 mln (US$ 1,344)
20 cetuximab Erbitux
EGF-R Rec chimeric mab
Bristol-Myers Squibb & Merck Serono (from ImClone)
Antibody Refractory meta-static colorectal cancer; Head & neck cancer
US$ 1,416 mln (US$ 1,095)
5/20 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2007 March 27, 2008 | Special Edition 1
No. Previous
Year Class of Products 2007 sales
(US$ bln.) Change vs
2006 Selected Branded Products
1 2 Major cancer antibodies 15.74 + 48 % Rituxan/MabThera, Herceptin, Avastin, Erbitux, Vectibix
2 3 Anti-TNF antibodies 12.98 + 26.3 % Enbrel, Remicade, Humira
3 1 Erythropoietins 11.82 - 1 % Aranesp, Procrit Eprex, Epogen, Neo-Recormon, ESPO
4 4 Insulin and insulin analogs 11.19 + 24.7 % Humalog, Humulin, Lantus, Levemir, Novorapid, Actrapid, Novolin
5 5 Rec. coagulation factors 5.39 + 14.4 % Novoseven, Kogenate, Helixate, Refacto, Advate, Recombinate, Benefix
6 6 Interferon beta 5.35 + 21.5 % Avonex, Rebif, Betaferon / Betaseron
7 7 G-CSF 4.82 + 10.4 % Neulasta, Neupogen, Neutrogin, GRAN
8 8 Human growth hormone 2.77 + 12.1 % Genotropin, Norditropin, Humatrope, Nutropin, Saizen, Serostim
9 9 Interferon alpha 2.74 + 21.4 % Pegasys, Peg-Intron, Intron A
10 10 Enzyme Replacement 2.29 + 34.1 % Cerezyme, Fabrazyme, Aldurazyme, Myozyme, Replagal, Naglazyme, Elaprase
11 - Ophthalmic antibody 1.36
- Lucentis
12 12 Follicel stimulating hormone
~ 1.28 + 21.8 % Gonal-f, Puregon/Follistim
13 11 Antiviral antibody > 1.13 + 2.3 % Synagis
Total:
78.86
+ 15 %
6/20 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2007 March 27, 2008 | Special Edition 1
Product Type: Pharmaceutical Category: Cancer antibodies - No. 1
ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication 1st approval
2007 sales (mln) vs. previous year (%)
Rituxan / MabThera; rituximab
CD20 Rec chimeric mab
Genentech/ Roche /Chugai Biogen IDEC Zenyaku Kogyu
Antibody 1st line treat-ment of diffuse, large B-cell, CD20+ NHL plus chemotherapy
1997 CHF 5,516 (+ 15 %) = US$ 5,392* source
Herceptin, trastuzumab
HER2 Rec humanized mab
Roche / Genentech
Antibody Metastatic breast cancer
CHF 4,852 (+ 23 %) = US$ 4,743* source
Avastin; bevacizumab
VEGF Rec humanized mab
Roche / Genentech
Antibody Metastatic colorectal cancer
CHF 4,106 (+ 41) = US$ 4,014* source
Erbitux; cetuximab
EGF-R Rec chimeric mab
Bristol-Myers Squibb & Merck Serono (from ImClone)
Antibody Refractory metastatic colorectal cancer; Head & neck cancer
BMS = US: US$ 692 (+ 6 %) source Merck Serono = Non-US: € 470 mln (+ 40 %) = US$ 724 source total Erbitux sales: US$ 1,416
Vectibix; panitumu-mab
EGF-R Rec fully human mab
Amgen Antibody 3rd line metastatic colorectal cancer
2006 US$ 170 (+ 336 %) source
Total: US$ 15,735
* strong influence of currency exchange rate (CHF into US$)
6
7/20 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2007 March 27, 2008 | Special Edition 1
Product Type: Pharmaceutical Category: Anti-TNF Biologics– No. 2
ID Product Target / Class of Company Product Indication 1st 2007 sales (mln) No. Name Mechanism Compound Category appr vs. previous year (%)
of Action oval Enbrel; TNF-alpha Fusion
protein of Fc + sol TNF-R
Amgen Fusion protein
Rheumatoid arthritis; psoriasis etc
North America: US$ 3,230 (+ 12 %) etanercept source
Ex-US and Canada: US$ 2,045 (+ 36 %)
Wyeth Fusion protein
Rheumatoid arthritis; psoriasis etc
Enbrel; TNF-alpha Fusion protein of Fc + sol TNF-R
(from Amgen) etanercept source
Fusion protein
Rheumatoid arthritis
03/ Q2-4: Y 14.3 bln Takeda Phar-maceuticals (from Wyeth)
Embrel; TNF-alpha Fusion protein of Fc + sol TNF-R
source 2005 etanercept Extrapolated Q1-4: Yen 19 bln (+
66.5 %) = US$ 177.6 Co-promotion with Wyeth KK
Remicade; infliximab
TNF-alpha Rec chimeric mab
Centocor / J&J Antibody Rheumatoid arthritis etc
Exclusive US$ = 2,534 (+ 7.6 %) + Intl to partners (793: + 20.5 %)
(10 indications) Total: US$ 3,327 source Forecast fiscal year 2007: Antibody Rheumatoid
arthritis; psoriasis etc
Remicade; infliximab
TNF-alpha Rec chimeric mab
Tanabe Seiyaku Yen 28.3 bln (+ 38 %)
= US$ 283 (from Centocor)
source for Japan and certain Asian countries
Remicade; infliximab
TNF-alpha Rec chimeric mab
Schering-Plough
Antibody Rheumatoid arthritis; psoriasis etc
US$ 1,648 (+ 33 %*) source For non-US territory = RoW except US, Japan and certain Asian countries (Tanabe territories)
US$ 3,064 (+ 49.9 %) Humira TNF-alpha Rec fully human mab
Abbott Antibody Rheumatoid arthritis, psoriasis etc
source adalimumab (& Eisai) Approved in six indications
Total: US$ 12,982
8/20 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2007 March 27, 2008 | Special Edition 1
Product Type: Pharmaceutical Category: EPOs – No. 3
ID Product Target / Class of Company Product Indication 1st 2007 sales (mln) No. Name Mechanism
of Action Compound Category appr
oval vs. previous year (%)
Aranesp; darbepoetin
EPO-receptor Glyco-engineered rhu protein
Amgen Protein Renal and cancer anemia
US$ 3,614 (- 12 %) source
5
Kirin Pharma Protein Anemia 07/ 2007
Combined sales of ESPO + NESP: EPO-R Glyco-engineered rhu protein
NESP; (from Amgen) Yen 41.7 bln (+ 0.3 %) = US$ 390
mln darbepoetin; KRN321 source
Procrit / Eprex;
EPO-R Rhu protein Johnson & Johnson
Protein Renal and cancer anemia
US$ 2,885 (- 12 %) source
epoetin alfa (from Amgen) Epogen; EPO-R Rhu protein Amgen Protein Renal and
cancer anemia US$ 2,489 (- 1 %) source
epoetin alfa ESPO; EPO-R Rhu protein Kirin Pharma Protein Anemia Combined sales of ESPO + NESP:
epoetin alfa (from Amgen) Yen 41.7 bln (+ 0.3 %) = US$ 390 mln source > 50 % market share
EPO-R Rhu protein Roche & Chugai
Protein Renal and cancer anemia
NeoRecormon: CHF 1,536 (- 4 %) = US$ 1501
Neo-recormon / Epogin; Epogin: CHF 558 (- 14 %) = US$
545 epoetin beta Combined epoetin beta sales: CHF 2,094 (- 7 %) = US$ 2,047 source
Total: US$ 11,815
9/20 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2007 March 27, 2008 | Special Edition 1
Product Type: Pharmaceutical Category: Insulin products – No. 4
ID Product Target / Class of Company Product Indication 1st 2007 sales (mln) No. Name Mechanism Compound Category appr vs. previous year (%)
of Action oval Humalog;
insulin lispro Insulin receptor
Rhu insulin analog
Eli Lilly Protein Diabetes US$ 1,475 (+ 13 %) source
Humulin Insulin receptor
Rhu insulin Eli Lilly Protein Diabetes US$ 985 (+ 6 %) source
Lantus; insulin glargine
Insulin receptor
Rhu insulin analog once daily
Sanofi-Aventis Protein Diabetes mellitus
€ 2,031 (+ 21.9 %) = US$ 3,167 source
Novo Nordisk Protein Diabetes Combined sales of Novo’s insulin analogs: DKK 14,008 (+ 29 %)
Levemir Insulin receptor
Rhu (basal) insulin analogue detemir
= US$ 2,929 source
Novo Nordisk Protein Diabetes NovoLog (Mix)
Insulin receptor
Rhu rapid acting insulin analogue aspart
Actrapid / Novolin; Insulatard; Mixtard
Insulin receptor
Rhu insulin and related products
Novo Nordisk Protein Diabetes Human insulins: DKK 12,572 (- 7 %) = US$ 2,629 source
Total: US$ 11,185
8
10/20 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2007 March 27, 2008 | Special Edition 1
Product Type: Pharmaceutical Category: Rec. coagulation factors – No 5
ID Product Target / Class of Company Product Indication 1st 2007 sales (mln) No. Name Mechanism Compound Category appr vs. previous year
of Action oval NovoSeven; Coagulation
factor replacement
Rhu factor VIIa
Novo Nordisk Protein Hemophilia DKK 5,865 (+ 4 %) = US$ 1,226 eptacog alfa source
Bayer Schering Pharma
Protein Hemophilia A € 818 ( + 3.9 %) = US$ 1,276 Rhu factor VIII + need-le-free inject
Kogenate FS + BioSet;
Coagulation factor replacement
source octocog
Helixate FS Factor VIII substitution
Rhu factor VIII formul. with sucrose
CSL Behring Cardio-vascular & blood
Hemophilia A Fully year 2006/7: 17 % of AUS$ 2.6 bln (442) = US$ 403 mln (from Bayer
Schering) source (H2/2007 = AUS$ 228 = US$ 208 source )
Hemophilia A 2007 sales > US$ 1,200 Baxter Cardio-vascular & blood
Advate; Factor VIII substitution
Plasma + albumin free processed rhu protein
source rAHF
RecombinaterAHF
Factor VIII substitution
Rhu factor VIII
Baxter Cardio-vascular & blood
Hemophilia A Combined 2007 sales of Recombinate and Advate = US$ 1,714 mln (+ 13 %)
(from GI/Wyeth) source Wyeth Protein Hemophilia A US$ 335 (+ 9.6 %) Rhu B-dom-
ain deleted factor VIII
Refacto Coagulation factor replacement
source
Benefix; Coagulation factor replacement
Rhu factor IX Wyeth Protein Hemophilia B US$ 433 (+ 21 %) source transition of rights to Wyeth since July 2007 in EMEA states
Nonacog alfa reformulated
Hemophilia B < US$ 43 (all hospital distributed products incl. BeneFIX)
Cardio-vascular & blood
Baxter (exclusive in Europe)
BeneFIX; Substitution of factor IX
Rec human factor IX reformulated
Nonacog alfa - not considered - reformulated
Total: US$ 5,387
11/20 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2007 March 27, 2008 | Special Edition 1
Product Type: Pharmaceutical Category: Interferon beta – No- 6
ID Product Target / Class of Company Product Indication 1st 2007 sales (mln) No. Name Mechanism Compound Category appr vs. previous year (%)
of Action oval Avonex;
inteferon beta-1a
IFN-R Rhu interferon β-1a
Biogen Idec Protein Multiple sclerosis US$ 1,868 (+ 9 %) source
Merck Serono & Pfizer
Protein Multiple sclerosis EURO 1,218 (+ 5.3 %)= US$ 1,875
IFN-R Rhu interferon β-1a
Rebif; interferon beta-1a
source reporting of Merck Serono includes Pfizer sales source
Bayer Schering Pharma
Protein Multiple sclerosis € 1,028 (+ 3.7 % pro forma) = US$ 1,603
IFN-R Rhu interferon β-1b
Betaferon / Betaseron; sourceinterferon beta-1b
Total: US$ 5,346
12/20 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2007 March 27, 2008 | Special Edition 1
Product Type: Pharmaceutical
Category: G-CSF – No. 7
ID Product Target / Class of Company Product Indication 1st 2007 sales (mln) No. Name Mechanism Compound Category appr vs. previous year (%)
of Action oval US$ 3,000 (+ 10.7 %) Neulasta;
peg-filgrastim
G-CSF-receptor
Pegylated Amgen Protein Neutropenia associated with chemotherapy
source rhu protein
Neupogen / GRAN;
G-CSF-receptor
Rhu protein Amgen Protein Neutropenia associated with chemotherapy
Amgen: US$ 1,277 (+5.3 %) source
filgrastim Kirin: Yen 15.2 bln (- 1 %) = US$ 142 mln sourceTotal: US$ 1,419 mln
CHF 405 (+ 13%) = US$ 396
Neutrogin; G-CSF-receptor
Rhu protein Chugai Protein Neutropenia associated with chemotherapy
lenograstim (Roche) source
Total: > US$ 4,815
11
13/20 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2007 March 27, 2008 | Special Edition 1
Product Type: Pharmaceutical Category: human Growth Hormone – No. 8
ID Product Target / Class of Company Product Indication 1st 2007 sales (mln) No. Name Mechanism Compound Category appr vs. previous year (%)
of Action oval Genotropin Regulation of
postnatal growth
Rec human protein
Pfizer Protein Growth hormone deficiency
US$ 843 (+ 6 %) source
Norditropin Regulation of postnatal growth
Rec human protein
Novo Nordisk Protein Growth hormone deficiency
DKK 3,511 (+ 6 %) = US$ 734 source
Rec human protein
Eli Lilly Protein Growth hormone deficiency
Estimate of US$ 441 (+ 6 % ) Humatrope; Regulation of postnatal growth
source
Nutropin; Protropin; somatropin; somatrem
Regulation of postnatal growth
Rec human protein
Genentech (Roche)
Protein Growth hormone deficiency
CHF 470 (- 1) = US$ 459 source
Protein Growth hormone deficiency
€ 23.7 (+ 61 %) = US$ 37 Rec human protein
Ipsen Nutropin AQ Pen; somatropin
Regulation of postnatal growth
(from Genen-tech / Roche)
source License for RoW except North America and Japan
Rec human protein
Merck Serono Protein Growth hormone deficiency
Saizen: EURO 163.1 (- 2 %) = US$ 254
Saizen / Regulation of postnatal growth
Serostim source
Total: US$ 2,768
1
14/20 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2007 March 27, 2008 | Special Edition 1
Product Type: Pharmaceutical Category: Interferon alfa – No. 9
Product Target / Class of Company Product Indication 1st 2007 sales (mln) Name Mechanism Compound Category appr vs. previous year (%)
of Action oval Pegasys;
peginterfer-on alfa-2a
IFN-R Pegylated rec hu protein
Roche Protein Hepatitis B and C
CHF 1,637 (+ 11 %) = US$ 1,600 source
US$ 911 (+ 9 %) Peg-Intron; pegylated IFN alfa-2b
IFN-R Pegylated rhu protein
Schering-Plough
Protein Hepatitis C source
Intron A; interferon alfa-2b
IFN-R Rhu protein Schering- Plough
Protein Hepatitis US$ 233 (- 2 %) source
Total: US$ 2,744
1
15/20 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2007 March 27, 2008 | Special Edition 1
Product Type: Pharmaceutical Category: Enzyme Replacement – No. 10
Product Target / Class of Company Product Indication 1st 2007 sales (mln) Name Mechanism Compound Category appr vs. previous year
of Action oval Cerezyme;
imiglucerase Beta-gluco-cerebrosidase replacement
Imiglucerase for injection
Genzyme Protein Gaucher’s disease
US$ 1,133 (+ 12.5 %) source
Rhu enzyme Genzyme Protein Fabry disease US$ 424 (+ 18.1 %) Fabrazyme; Alpha galactosidse A replacement
sourceagalsidase beta
Rhu enzyme Genzyme Protein Pompé disease US$ 201 (+ 239 % ) Myozyme; Acid-alpha-glucosidase replacement
sourcealglucosidase alfa
US$ 123.7 (+ 28.5 %) Aldurazyme; laronidase
Alpha-L-iduronidase replacement
Rhu enzyme Genzyme & BioMarin
Protein Hurler and Hurler-Scheie forms of mucopoly-
source Total product sales of Joint Venture
saccharidosis I (MPS I)
Elaprase; Iduronate-2-sulfatase replacement
Rhu enzyme Shire Protein Hunter syndrome
2006 US$ 181.8 (+ 670 %) source idursulfase (from TKT)
(MPS II) Replagal; Alpha-
galactosidase replacement
Rhu enzyme Shire & Protein Fabry disease US$ 143.9 (+ 22 %) sourceagalsidase alfa
Dainippon Sumitomo
In Japan approved in Oct 2007
Rhu enzyme BioMarin Protein MPS VI US$ 86.2 (+ 85.4 %) Naglazyme; N-acetyl-galactosamine 4-sulfatase replacement
sourcegalsulfase
Total: US$ 2,293.6
16/20 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2007 March 27, 2008 | Special Edition 1
Product Type: Pharmaceutical Category: Ophthalmic antibody - 11
Product Target / Class of Company Product Indication 1st 2007 sales (mln) Name Mechanism Compound Category appr vs. previous year
of Action oval Genentech for US: CHF 991 = US$ 969 (+ 117 %)
Lucentis; VEGF Rec humanized Fab
Genentech (Roche) & Novartis
Antibody Wet age-related macular degeneration
2006 US; 2007 EU
ranibizumab source Novartis for ex-US: US$ 393 source Total : US$ 1,362
Product Type: Pharmaceutical Category: Follicle stimulating hormones – No. 12
Product Target / Class of Company Product Indication 1st 2007 sales (mln) Name Mechanism Compound Category appr vs. previous year (%)
of Action oval Gonal-f;
follitropin alfa
FSH-R Rhu protein Merck Serono Protein Infertility EURO 434.2 (+ 2 %) = US$ 668 source
Puregon; Follistim follitropin beta
FSH-R Rhu protein Schering-Plough
Protein Infertility US$ 57 mln (from Nov 19 to Dec 31, 2007) source
(ex Organon) 2006 sales: € 384 (+ 8 %) = US$ 599 source
Approximately Total: US$ 1,267
Product Type: Pharmaceutical Category: Antiviral antibody – No. 13
Product Target / Class of Company Product Indication 1st 2007 sales (mln) Name Mechanism Compound Category appr vs. previous year
of Action oval 1999 Jan – March 2007: US$ 507 Rec huma-
nized mab AstraZeneca (MedImmune)
Antibody Prevention of RSV in pre-mature infants
Synagis, Respiratory syncytical virus
source palivizumab June – Dec 2007: US$ 618 source
Total 2007 sales > US$ 1,125
17/20 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2007 March 27, 2008 | Special Edition 1
Product Type: Pharmaceutical Category: Selected Other Recombinant Biologics
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication 1st approval
2007 sales (mln) vs. previous year (%)
Forteo; teriparatide
PTH-R Rhu peptide (PTH 1-34)
Eli Lilly Peptide Osteoporosis US$ 709 (+ 19 %) source
Preotact (EU) / Preos (US)
PTH-R Rhu peptide (PTH 1-84)
Nycomed (from NPS Pharma-ceuticals)
Peptide Osteoporosis 2006 € 18 mln (+ 2,395 %) = US$ 28 source
Raptiva; efalizumab
CD11a Rec humanized mab
Genentech (Roche) & Merck Serono
Antibody Mild to moderate psoriasis
Roche: CHF 144 (+ 15 %) = US$ 141 source Ex-US : EURO 76.3 (+ 37 %) = US$ 117 source Total: US$ 258
Pulmozyme; dornase alfa
DNA Rhu protein Genentech (Roche)
Protein Cystic fibrosis CHF 483 (+ 12 %) = US$ 472 source
Orencia; abatacept
CD80/CD86 (B7.1 + B7.2)
Rec fusion protein of CTLA4 + Fc
Bristol-Myers Squibb
Fusion protein
Rheumatoid arthritis
2005 US$ 231 (+ 216 %) source
Xolair; omalizumab
IgE Rec humanized mab
Genentech (Roche) & Novartis
Antibody Asthma Roche: CHF 567 (+ 10 %) = US$ 554 source Novartis: US$ 140 (+ 30 %) sourceCombined : US$ 694
BMP-2; rhBMP2; InductOs
Tissue regeneration
Rhu growth factor
Wyeth Protein Spinal fusion + long bone fusion
US$ 359 (+ 16.5 %), mainly in US source
Activase / Alteplase; Metalyse / TNKase; tenecteplase
Plasminogen Rec hu protein or rhu mutant protein
Genentech (Roche) & Boehringer Ingelheim
Protein Acute myocardial infarction; ischemic stroke
Genentech: CHF 382 (+ 9 %) = US$ 373 source Boehringer Ingelheim 2006 sales of both proteins: EURO 159 source in H1/2007 – 11 %
18/20 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2007 March 27, 2008 | Special Edition 1
Product Type: Pharmaceutical Category: Selected Other Recombinant Biologics
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication 1st approval
2007 sales (mln) vs. previous year (%)
Tysabri; natalizumab
Alpha4 integrin
Rec humanized mab
Biogen Idec & Elan
Antibody Multiple sclerosis; Crohn’s disease
Biogen Idec: US$ 230 source Elan: US$ 343 source
Xigris; Drotrecogin alfa
Activated protein C
Rhu protein Lilly Protein High risk severe sepsis
US$ 182.8 (- 5 %) source
Actemra; tocilizumab
Interleukin-6 receptor
Rec humanized mab
Roche (Chugai)
Antibody Rheumatoid arthritis
CHF 5 = US$ 5 (+ 21 %) source
19/20 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2007 March 27, 2008 | Special Edition 1
Product Type: Pharmaceutical Category: Selected Other Non-recombinant Biologics
Product Target / Class of Company Product Indication 1st 2007 sales (mln) Name Mechanism Compound Category appr vs. previous year (%)
of Action oval Copaxone; Immuno-
modulator Peptide Sanofi-Aventis
& Teva Peptide Multiple sclerosis 1997 (Sanofi-Aventis: EURO 1,177 (+
10.1 %) Glatiramer acetate
source ) Teva: global sales: US$ 1,713 (+ 21 %) source
Botox; botulinum toxin type A
Neuro-muscular blockade
Botulinum neurotoxin type A
Allergan & GSK (Japan and China)
Peptide Aesthetic and medical indications
Allergan: US$ 1,212 mln (+23.4 %) source ; Allergan receives royalties from GSK not included in sales figure
Botulinum neurotoxin type A
Dysport (EU); Reloxin (US); botulinum toxin type A
Neuro-muscular blockade
Medicis Peptide Aesthetic medicine indications
2007 sales of € 128.7 mln (+ 13.6 %) (NA + J) & source
Galderma (EU)
(from Ipsen)
Byetta; GLP-1 receptor
GLP-1 analog Eli Lilly & Amylin Phar-maceuticals
Peptide Diabetes 2005 US$ 650 (+ 48 %) sourceexenatide
Fuzeon, HIV entry inhibitor
Linear 36-aa synthetic peptide
Roche & Trimeris
Peptide HIV CHF 320 (+ 3 %) = US$ 313 enfuvirtide source
Integrilin GP IIb/IIIa Peptide Schering-Plough
Peptide Acute coronary syndrome
US$ 332 (+ 1 %) source
ReoPro; GP IIb/IIIa Peptide Lilly Peptide Acute coronary syndrome
US$ 270.3 (- 4 %) sourceabciximab
20/20 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2007 March 27, 2008 | Special Edition 1
Why should you use R&D Pipeline N ?
Learn more about R&D Pipeline News
• To keep up-to-date.
R&D Pipeline News is your weekly tool for biopharmaceutical R&D analysis and it's available by annual subscription.
Examine the who, what, when, where of biotechnology R&D.
R&D Pipeline News will keep you up-to-date with the latest R&D projects of the biopharmaceutical industry, with all the relevant treatment modalities and with competitive information about ongoing R&D projects for a given Target, Technology or Company.
• To benchmark your company against the competition
Keep en eye on your competitors’ projects and developments, in which stage they are, their achievements, handicaps, etc…and find out where you are standing in the market. The R&D information is presented in an easy- and rapid-to-
screen tabular format and grouped either in Therapeutic Areas or Product Categories, saving you time in your research.
• To save time in your research
Get the crucial information, in a one-shot tabular screen grouped in Therapeutic Areas or Product Categories, and deepen easily in those articles in which you are interested with just one-click.
Where can I get a subscription?
• To identify new business enterprises Just visit our Online Store at www.pipelinereview.com
Recognize new business opportunities: joint ventures, licensing partners, co-marketing partners, etc..
• To receive news right in time
Get your personal copy every monday delivered by e-mail.
Or contact us at [email protected]